Pre-made Iscalimab benchmark antibody ( Whole mAb, anti-CD40 therapeutic antibody, Anti-p50/Bp50/CDW40/TNFRSF5 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Iscalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

CFZ533 (ISCALIMAB) is a fully human antibody that blocks CD40, a co-stimulatory protein involved in the activation of immune B-cells, which are crucial to the development of Sjogren's syndrome. It is currently in Phase II of clinical trial for Sjogren's Syndrome.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-280-1mg	1mg	3090
GMP-Bios-ab-280-10mg	10mg	Inquiry
GMP-Bios-ab-280-100mg	100mg	Inquiry
GMP-Bios-ab-280-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Iscalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody
INN Name	Iscalimab
Target	CD40
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Novartis;XOMA
Conditions Approved	na
Conditions Active	Graves' disease;Lupus nephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic lupus erythematosus
Conditions Discontinued	Rheumatoid arthritis
Development Tech	na